These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25596619)

  • 1. Preserved outer retina in AIPL1 Leber's congenital amaurosis: implications for gene therapy.
    Aboshiha J; Dubis AM; van der Spuy J; Nishiguchi KM; Cheeseman EW; Ayuso C; Ehrenberg M; Simonelli F; Bainbridge JW; Michaelides M
    Ophthalmology; 2015 Apr; 122(4):862-4. PubMed ID: 25596619
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of Italian patients with leber congenital amaurosis due to AIPL1 mutations highlights the potential applicability of gene therapy.
    Testa F; Surace EM; Rossi S; Marrocco E; Gargiulo A; Di Iorio V; Ziviello C; Nesti A; Fecarotta S; Bacci ML; Giunti M; Della Corte M; Banfi S; Auricchio A; Simonelli F
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5618-24. PubMed ID: 21474771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
    Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
    Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis.
    Pasadhika S; Fishman GA; Stone EM; Lindeman M; Zelkha R; Lopez I; Koenekoop RK; Shahidi M
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2608-14. PubMed ID: 19959640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leber congenital amaurosis associated with AIPL1: challenges in ascribing disease causation, clinical findings, and implications for gene therapy.
    Tan MH; Mackay DS; Cowing J; Tran HV; Smith AJ; Wright GA; Dev-Borman A; Henderson RH; Moradi P; Russell-Eggitt I; MacLaren RE; Robson AG; Cheetham ME; Thompson DA; Webster AR; Michaelides M; Ali RR; Moore AT
    PLoS One; 2012; 7(3):e32330. PubMed ID: 22412862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual electroretinograms in young Leber congenital amaurosis patients with mutations of AIPL1.
    Pennesi ME; Stover NB; Stone EM; Chiang PW; Weleber RG
    Invest Ophthalmol Vis Sci; 2011 Oct; 52(11):8166-73. PubMed ID: 21900377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual acuity in patients with Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa.
    Walia S; Fishman GA; Jacobson SG; Aleman TS; Koenekoop RK; Traboulsi EI; Weleber RG; Pennesi ME; Heon E; Drack A; Lam BL; Allikmets R; Stone EM
    Ophthalmology; 2010 Jun; 117(6):1190-8. PubMed ID: 20079931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human retinal disease from AIPL1 gene mutations: foveal cone loss with minimal macular photoreceptors and rod function remaining.
    Jacobson SG; Cideciyan AV; Aleman TS; Sumaroka A; Roman AJ; Swider M; Schwartz SB; Banin E; Stone EM
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):70-9. PubMed ID: 20702822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene and Cell Therapy for AIPL1-Associated Leber Congenital Amaurosis: Challenges and Prospects.
    Perdigao PRL; van der Spuy J
    Adv Exp Med Biol; 2019; 1185():97-101. PubMed ID: 31884595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinal disease in Rpe65-deficient mice: comparison to human leber congenital amaurosis due to RPE65 mutations.
    Caruso RC; Aleman TS; Cideciyan AV; Roman AJ; Sumaroka A; Mullins CL; Boye SL; Hauswirth WW; Jacobson SG
    Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5304-13. PubMed ID: 20484585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis.
    Ku CA; Chiodo VA; Boye SL; Goldberg AF; Li T; Hauswirth WW; Ramamurthy V
    Hum Mol Genet; 2011 Dec; 20(23):4569-81. PubMed ID: 21880665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Leber Congenital Amaurosis-Linked Protein AIPL1 and Its Critical Role in Photoreceptors.
    Sacristan-Reviriego A; van der Spuy J
    Adv Exp Med Biol; 2018; 1074():381-386. PubMed ID: 29721967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.
    Simonelli F; Maguire AM; Testa F; Pierce EA; Mingozzi F; Bennicelli JL; Rossi S; Marshall K; Banfi S; Surace EM; Sun J; Redmond TM; Zhu X; Shindler KS; Ying GS; Ziviello C; Acerra C; Wright JF; McDonnell JW; High KA; Bennett J; Auricchio A
    Mol Ther; 2010 Mar; 18(3):643-50. PubMed ID: 19953081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pupillometric quantification of residual rod and cone activity in leber congenital amaurosis.
    Kawasaki A; Munier FL; Leon L; Kardon RH
    Arch Ophthalmol; 2012 Jun; 130(6):798-800. PubMed ID: 22801849
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigation of PTC124-mediated translational readthrough in a retinal organoid model of AIPL1-associated Leber congenital amaurosis.
    Leung A; Sacristan-Reviriego A; Perdigão PRL; Sai H; Georgiou M; Kalitzeos A; Carr AF; Coffey PJ; Michaelides M; Bainbridge J; Cheetham ME; van der Spuy J
    Stem Cell Reports; 2022 Oct; 17(10):2187-2202. PubMed ID: 36084639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. My child has Leber congenital amaurosis: why is he/she not eligible for gene therapy trials?
    Héon E
    J AAPOS; 2009 Dec; 13(6):533-4. PubMed ID: 19896875
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvement and decline in vision with gene therapy in childhood blindness.
    Jacobson SG; Cideciyan AV; Roman AJ; Sumaroka A; Schwartz SB; Heon E; Hauswirth WW
    N Engl J Med; 2015 May; 372(20):1920-6. PubMed ID: 25936984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Potential for LCA5-Associated Leber Congenital Amaurosis.
    Uyhazi KE; Aravand P; Bell BA; Wei Z; Leo L; Serrano LW; Pearson DJ; Shpylchak I; Pham J; Vasireddy V; Bennett J; Aleman TS
    Invest Ophthalmol Vis Sci; 2020 May; 61(5):30. PubMed ID: 32428231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel.
    Banin E; Bandah-Rozenfeld D; Obolensky A; Cideciyan AV; Aleman TS; Marks-Ohana D; Sela M; Boye S; Sumaroka A; Roman AJ; Schwartz SB; Hauswirth WW; Jacobson SG; Hemo I; Sharon D
    Hum Gene Ther; 2010 Dec; 21(12):1749-57. PubMed ID: 20604683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
    Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
    Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.